Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis

• ClinicalTrials.gov Identifier: NCT00425932
• Recruitment Status: Completed
• First Posted: January 24, 2007
• Last Update Posted: August 22, 2013
• Sponsor: Gaylis, Norman B., M.D.
• Collaborators: Oklahoma Medical Research Foundation; Genentech, Inc.
• Information provided by (Responsible Party): Gaylis, Norman B., M.D.

Tracking Information

• First Submitted Date: January 22, 2007
• First Posted Date: January 24, 2007
• Last Update Posted Date: August 22, 2013
• Study Start Date: February 2007
• Actual Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: April 24, 2008): The primary endpoint fo the trial is change in 1.5 Tesla MRI erosion score (RAMRIS system) from baseline to Week 24. [ Time Frame: 24 weeks ]
• Original Primary Outcome Measures (submitted: January 22, 2007): The primary endpoint fo the trial is change in 1.5 Tesla MRI erosion score (RAMRIS system) from baseline to Week 24.

Current Secondary Outcome Measures (submitted: April 24, 2008)

• Change from Baseline in 1.5 Tesla MRI synovitis score (RAMRIS system) at Week 12. [ Time Frame: 12 weeks ]
• Change from Baseline in 1.5 Tesla MRI bone edema and total score (RAMRIS system) at Week 24. [ Time Frame: 24 weeks ]
• Change from Baseline in 1.5 Tesla MRI bone edema, bone erosion and total score (RAMRIS system) at Week 12 and Week 48. [ Time Frame: 12 and 48 weeks ]
• Proportion of patients at Week 48 without new bone erosions on 1.5 Tesla MRI. [ Time Frame: 48 weeks ]
• Change from baseline in total Genant modified Sharp score on conventional radiographs at Week 24 and 48. [ Time Frame: 24 and 48 weeks ]
• Change in Disease Activity Score (DAS 28) from Baseline to Week 24 and 48. [ Time Frame: 24 and 48 weeks ]
• ACR remission and responder rates (20%, 50%, &)%) at Week 24 and 48. [ Time Frame: 24 and 48 weeks ]
• Change from Baseline in functional assessments according to the HAQ scores at 24 and 48 Weeks. [ Time Frame: 24 and 48 weeks ]
• Difference between relative results from conventional high-field strength 1.5 Tesla MRI and 0.2 Tesla dedicated extremity MRI in detection and grading of bone erosions, bone edema, and synovitis at Baseline and in Week 12,24, and 48 (C-scan validation). [ Time Frame: 12, 24 and 48 weeks ]

Original Secondary Outcome Measures (submitted: January 22, 2007)

• Change from Baseline in 1.5 Tesla MRI synovitis score (RAMRIS system) at Week 12.
• Change from Baseline in 1.5 Tesla MRI bone edema and total score (RAMRIS system) at Week 24.
• Change from Baseline in 1.5 Tesla MRI bone edema, bone erosion and total score (RAMRIS system) at Week 12 and Week 48.
• Proportion of patients at Week 48 without new bone erosions on 1.5 Tesla MRI.
• Change from baseline in total Genant modified Sharp score on conventional radiographs at Week 24 and 48.
• Change in Disease Activity Score (DAS 28) from Baseline to Week 24 and 48.
• ACR remission and responder rates (20%, 50%, &)%) at Week 24 and 48.
• Change from Baseline in functional assessments according to the HAQ scores at 24 and 48 Weeks.
• Difference between relative results from conventional high-field strength 1.5 Tesla MRI and 0.2 Tesla dedicated extremity MRI in detection and grading of bone erosions, bone edema, and synovitis at Baseline and in Week 12,24, and 48 (C-scan validation).

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis
• Official Title: Impact of Rituximab on Magnetic Resonance Imaging Evidence of Synovitis and Bone Lesions in Patients With Moderate or Severe Rheumatoid Arthritis
• Brief Summary: The purpose of this study is to further investigate rituximab in the treatment of rheumatoid arthritis and to evaluate magnetic resonance imaging of the joints as a possible method to improve the evaluation of treatments.

Detailed Description

Rituximab is a monoclonal antibody that has been approved for the treatment of non-Hodgkin's B cell lymphoma (a type of cancer) and for certain patients with rheumatoid arthritis (RA) by the Food and Drug Administration (FDA). To date, more than 1000 subjects with rheumatoid arthritis have received rituximab in clinical studies.

Magnetic resonance imaging (MRI) is a modern and sensitive method of looking at joints in people with rheumatoid arthritis. It uses a magnetic field to create an image. The MRI takes an image in 3 dimensions and this provides a better picture for a physician to see more details.

There are two treatment groups in this study with equal numbers of patients assigned to each group. All the patients will receive their baseline Methotrexate and two intravenous infusions 2 weeks apart of one of the following:

• 1000 mg rituximab or
• placebo. Patients outcomes will be compared between the 2 groups. After week 24 (open label phase), the patients will receive rituximab if rheumatoid arthritis remains active.

All the patients will have MRI of their dominant hand and wrist with and without gadolinium performed at baseline, 12, 24 and 48 weeks on 1.5 Tesla MRI . Some patients will also have additional MRI of the same hand and wrist without gadolinium at the same time points on 0.2 Tesla MRI. Comparison of the images from the two machines will be performed.

Various blood biomarkers will also be examined, compared between the 2 treatment groups and correlated with the MRI results.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Crossover Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment
• Condition: Rheumatoid Arthritis

Intervention

Biological: Rituximab

At Week 24 or any time up to Week 48 if the Patient DAS 28 > 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.

Other Name: Rituxan

Study Arms

• No Intervention: Rituximab/Placebo
  Patients will be randomized at Baseline to either Placebo or Rituximab. At Week 24 and up to Week 48 if patient DAS28 score is >2.6, patient will be retreated with open label Rituximab.
• Active Comparator: Open Label
  At Week 24 or any time up to Week 48 if the Patient DAS 28 > 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.
  Intervention: Biological: Rituximab

• Publications *: Peterfy CG, Olech E, DiCarlo JC, Merrill JT, Countryman PJ, Gaylis NB. Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932). Arthritis Res Ther. 2013 Mar 20;15(2):R44. doi: 10.1186/ar4202.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: January 22, 2007): 60
• Original Enrollment: Same as current
• Actual Study Completion Date: November 2012
• Actual Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria

• Able and willing to give written informed consent
• Age 18-80 years
• Must have active rheumatoid arthritis for at least 12 weeks, but no more than 5 years.
• Must be receiving treatment on an outpatient basis
• Must have > 8 tender and swollen joints
• Must have negative serum pregnancy test
• Must have an inadequate response to MTX
• Must have elevated serology parameters
• Must have Positive RF or anti-CCP antibody, or radiographic evidence of at least one joint with definite erosion attributable to RA.
• Stable use of Corticosteroids is permitted
• Stable use of NSAIDs is permitted

Exclusion Criteria:

• History of or current inflammatory joint disease
• Functional class IV
• Any surgical procedure within 12 weeks
• Lack of peripheral venous access.
• Pregnancy or breast feeding.
• Significant cardiac or pulmonary disease.
• Evidence of significant uncontrolled concomitant disease
• Positive HIV
• Known active infection of any kind
• History of deep space/tissue infection
• History of recurrent significant infection
• Concomitant malignancies or previous malignancies
• Any neurological, vascular or systemic disorder
• History of drug, alcohol, or chemical abuse
• Inability to comply with study and follow-up procedures
• History of a severe allergic or anaphylactic reaction to a biologic agent
• Previous treatment with more than one biologic agent for RA. Patients must not have received a biologic agent within 2 months prior to the Baseline visit, except for etanercept, abatacept and anakinra for which a one month washout prior to Baseline visit is acceptable
• Previous treatment with an anti-alpha 4 integrin antibody or co-stimulation modulator.
• Previous treatment with any cell depleting therapies.
• Treatment with any investigational agent within 28 days
• Receipt of a live/attenuated vaccine within 28 days
• Ongoing use of high dose steroids (>10mg/day)
• Inra-articular or parental glucocorticoids within 4 weeks prior to baseline.
• Intolerance or contraindications to i.v. glucocorticoids.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 80 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT00425932
• Other Study ID Numbers: U3900s
• Has Data Monitoring Committee: Not Provided
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Gaylis, Norman B., M.D.
• Original Responsible Party: Not Provided
• Current Study Sponsor: Gaylis, Norman B., M.D.
• Original Study Sponsor: Same as current

Collaborators

• Oklahoma Medical Research Foundation
• Genentech, Inc.

Investigators

• Principal Investigator: Norman B Gaylis, MD; Arthritis & Rheumatic Disease Specialties
• Principal Investigator: Ewa Olech, M.D.; Oklahoma Medical Research Foundation

• PRS Account: Gaylis, Norman B., M.D.
• Verification Date: August 2013